Applied Therapeutics CEO Shendelman Steps Down

Dow Jones

2024-12-20

By Paul Ziobro

Applied Therapeutics Chief Executive Shoshana Shendelman is stepping down from the biopharmaceutical company, which named finance chief Les Funtleyder as interim CEO.

Applied Therapeutics also brought in industry veteran John Johnson as executive chairman. Johnson, age 66, has been CEO of Reaction Biology and Strongbridge Biopharma, and also has held leadership roles at companies including Johnson & Johnson, Eli Lilly, ImClone and Pfizer. The company on Friday cited Johnson's turnaround experience in naming him to the position.

"His experience leading pre-commercial businesses, deep knowledge of rare diseases and the commercialization process, along with his commitment to culture, are deeply aligned with Applied Therapeutics' priorities," said Teena Lerner, Applied Therapeutics' lead independent director.

Shendelman founded and led the company for the last eight years, during which the company completed several successful clinical trials, built commercial infrastructure and advanced the company's Aldose Reductase Inhibitor franchise across multiple disease areas.

Funtleyder, age 55, will continue to serve as CFO while taking on the interim CEO role.

Write to Paul Ziobro at paul.ziobro@wsj.com

(END) Dow Jones Newswires

December 20, 2024 07:35 ET (12:35 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2492417688"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2492417688\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2492417688?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-20 20:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492417688","market":"sg","top_or_hot":-1,"title":"Applied Therapeutics CEO Shendelman Steps Down","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Paul Ziobro \n</p>\n<p>\n  Applied <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Chief Executive Shoshana Shendelman is stepping down from the biopharmaceutical company, which named finance chief Les Funtleyder as interim CEO. \n</p>\n<p>\n  Applied Therapeutics also brought in industry veteran John Johnson as executive chairman. Johnson, age 66, has been CEO of Reaction Biology and Strongbridge Biopharma, and also has held leadership roles at companies including Johnson &amp; Johnson, Eli Lilly, ImClone and Pfizer. The company on Friday cited Johnson's turnaround experience in naming him to the position. \n</p>\n<p>\n  \"His experience leading pre-commercial businesses, deep knowledge of rare diseases and the commercialization process, along with his commitment to culture, are deeply aligned with Applied Therapeutics' priorities,\" said Teena Lerner, Applied Therapeutics' lead independent director. \n</p>\n<p>\n  Shendelman founded and led the company for the last eight years, during which the company completed several successful clinical trials, built commercial infrastructure and advanced the company's Aldose Reductase Inhibitor franchise across multiple disease areas. \n</p>\n<p>\n  Funtleyder, age 55, will continue to serve as CFO while taking on the interim CEO role. \n</p>\n<p>\n  Write to Paul Ziobro at paul.ziobro@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 20, 2024 07:35 ET (12:35 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Applied Therapeutics CEO Shendelman Steps Down</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApplied Therapeutics CEO Shendelman Steps Down\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-12-20 20:35</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Paul Ziobro \n</p>\n<p>\n  Applied <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Chief Executive Shoshana Shendelman is stepping down from the biopharmaceutical company, which named finance chief Les Funtleyder as interim CEO. \n</p>\n<p>\n  Applied Therapeutics also brought in industry veteran John Johnson as executive chairman. Johnson, age 66, has been CEO of Reaction Biology and Strongbridge Biopharma, and also has held leadership roles at companies including Johnson &amp; Johnson, Eli Lilly, ImClone and Pfizer. The company on Friday cited Johnson's turnaround experience in naming him to the position. \n</p>\n<p>\n  \"His experience leading pre-commercial businesses, deep knowledge of rare diseases and the commercialization process, along with his commitment to culture, are deeply aligned with Applied Therapeutics' priorities,\" said Teena Lerner, Applied Therapeutics' lead independent director. \n</p>\n<p>\n  Shendelman founded and led the company for the last eight years, during which the company completed several successful clinical trials, built commercial infrastructure and advanced the company's Aldose Reductase Inhibitor franchise across multiple disease areas. \n</p>\n<p>\n  Funtleyder, age 55, will continue to serve as CFO while taking on the interim CEO role. \n</p>\n<p>\n  Write to Paul Ziobro at paul.ziobro@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 20, 2024 07:35 ET (12:35 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2492417688","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492417688","pubTimestamp":1734698100,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Applied Therapeutics Chief Executive Shoshana Shendelman is stepping down from the biopharmaceutical company, which named finance chief Les Funtleyder as interim CEO.Applied Therapeutics also brought in industry veteran John Johnson as executive chairman. Johnson, age 66, has been CEO of Reaction Biology and Strongbridge Biopharma, and also has held leadership roles at companies including Johnson & Johnson, Eli Lilly, ImClone and Pfizer. The company on Friday cited Johnson's turnaround experience in naming him to the position.\"His experience leading pre-commercial businesses, deep knowledge of rare diseases and the commercialization process, along with his commitment to culture, are deeply aligned with Applied Therapeutics' priorities,\" said Teena Lerner, Applied Therapeutics' lead independent director.Shendelman founded and led the company for the last eight years, during which the company completed several successful clinical trials, built commercial infrastructure and advanced the c","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","APLT":"Applied Therapeutics Inc."},"translate_title":"应用治疗公司首席执行官申德尔曼辞职","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APLT":0.9,"LENZ":1},"content_text":"By Paul Ziobro \n\n\n  Applied Therapeutics Chief Executive Shoshana Shendelman is stepping down from the biopharmaceutical company, which named finance chief Les Funtleyder as interim CEO. \n\n\n  Applied Therapeutics also brought in industry veteran John Johnson as executive chairman. Johnson, age 66, has been CEO of Reaction Biology and Strongbridge Biopharma, and also has held leadership roles at companies including Johnson & Johnson, Eli Lilly, ImClone and Pfizer. The company on Friday cited Johnson's turnaround experience in naming him to the position. \n\n\n  \"His experience leading pre-commercial businesses, deep knowledge of rare diseases and the commercialization process, along with his commitment to culture, are deeply aligned with Applied Therapeutics' priorities,\" said Teena Lerner, Applied Therapeutics' lead independent director. \n\n\n  Shendelman founded and led the company for the last eight years, during which the company completed several successful clinical trials, built commercial infrastructure and advanced the company's Aldose Reductase Inhibitor franchise across multiple disease areas. \n\n\n  Funtleyder, age 55, will continue to serve as CFO while taking on the interim CEO role. \n\n\n  Write to Paul Ziobro at paul.ziobro@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 20, 2024 07:35 ET (12:35 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}